Literature DB >> 6086282

The beta-adrenoceptor-blocking drug propranolol prevents secretion of immunoreactive beta-endorphin and alpha-melanocyte-stimulating hormone in response to certain stress stimuli.

F Berkenbosch, I Vermes, F J Tilders.   

Abstract

Handled female Wistar rats were exposed to one of the following stress stimuli: restraint, electric foot shocks, passive avoidance situation, ether, or nembutal anesthesia followed by ip formalin or laparotomy. Trunk blood was collected 2-4 min after initiation of the stress stimulus for the determination of immunoreactive beta-endorphin (beta-ENDi), ACTH (ACTHi), and alpha-MSH (alpha-MSHi). All stressors evoked a rapid increase of circulating beta-ENDi to 0.75-2.10 ng/ml. All except passive avoidance situation also induced a rapid increase of plasma ACTHi to 0.45-0.70 ng/ml, whereas plasma alpha-MSHi increased after ether and restraint to 0.18-0.40 ng/ml but was not affected by formalin stress. To study the involvement of a beta-adrenoceptor mechanism in stress-induced peptide secretion, rats were treated with D-propranolol or L-propranolol 40 min before stress exposure. Propranolol did not prevent the increase of plasma ACTHi to any of the stressors studied. L-Propranolol but not its inactive D-isomer reduced (restraint, passive avoidance) or abolished (electric foot shocks) the increase in plasma beta-ENDi but did not affect the beta-ENDi response to other stressors (ether, formalin, laparotomy). Similarly, L-propranolol attenuated the alpha-MSHi response to restraint but not to ether stress. To discriminate between corticotroph or melanotroph origin of beta-ENDi released during stress, rats were treated with dexamethasone or were subjected to neurointermediate lobectomy (4 weeks). Neurointermediate lobectomy did not affect basal or stress-induced plasma ACTHi but resulted in undetectable alpha-MSHi levels. It largely prevented the beta-ENDi response to restraint stress (propranolol sensitive) but had little effect on the beta-ENDi response to formalin stress (propranolol insensitive). Conversely, dexamethasone prevented stress-induced ACTHi response without affecting plasma alpha-MSHi. The beta-ENDi response to restraint stress (propranolol sensitive) was not changed but the response to formalin stress (propranolol insensitive) was largely prevented by dexamethasone. These results show that the intermediate lobe is the main source of beta-ENDi secreted during exposure to stressors with a high emotional impact. Since intermediate lobe peptide secretion induced by such stimuli can be prevented by beta-adrenoceptor blockade, we speculate that stress-induced discharge of catecholamines, possibly from the adrenal medulla, is the trigger signal for peptide secretion from the melanotrophs during this type of stress.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6086282     DOI: 10.1210/endo-115-3-1051

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  5 in total

Review 1.  Measuring the activity of brain adrenergic receptors in man.

Authors:  S al-Damluji
Journal:  J Endocrinol Invest       Date:  1991-03       Impact factor: 4.256

2.  Stress induced ACTH release in capsaicin treated rats.

Authors:  R Amann; F Lembeck
Journal:  Br J Pharmacol       Date:  1987-04       Impact factor: 8.739

3.  Stress-induced peptide release from rat intermediate pituitary. An ultrastructural analysis.

Authors:  J A Carr; L C Saland; A Samora; S Desai; S Benevidez
Journal:  Cell Tissue Res       Date:  1990-09       Impact factor: 5.249

4.  Dopamine D1 and D2 dopamine receptors regulate immobilization stress-induced activation of the hypothalamus-pituitary-adrenal axis.

Authors:  Xavier Belda; Antonio Armario
Journal:  Psychopharmacology (Berl)       Date:  2009-07-21       Impact factor: 4.530

5.  Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages.

Authors:  I Huitinga; N van Rooijen; C J de Groot; B M Uitdehaag; C D Dijkstra
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.